跳至主要内容
临床试验/ISRCTN16559899
ISRCTN16559899已完成未知

A Multicentre Randomised and Comparative Trial to Assess the Tolerance, Efficacy and Pharmacokinetics of Escalating Doses of Casodex Versus Castration in the Treatment of Advanced Carcinoma of the Prostate

AstraZeneca Clinical Research Group (UK)0 个研究点目标入组 248 人开始时间: 2002年8月19日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
248

研究概览

简要总结

2006 results in: https://www.ncbi.nlm.nih.gov/pubmed/16771791 (added 29/10/2019)

研究设计

研究类型
Interventional

入排标准

性别
Male

入选标准

  • 1. Histologically/cytologically confirmed metastatic or locally advanced (T3 or T4) prostate carcinoma. Confirmed within the last month
  • 2. Life expectancy of more than 3 months
  • 3. Prostate specific antigen (PSA) of at least five-times upper limit of normal reference range
  • 4. Evaluable disease and fit to receive any of the treatment options
  • 5. No previous or concurrent systemic therapy for prostate cancer
  • 6. No radiotherapy to the prostate within the 3 months prior to entry into the trial
  • 7. No previous medical history of another malignancy within the past 5 years
  • 8. Adequate cardiac, renal and hepatic function
  • 9. Eastern Cooperative Oncology Group (ECOG) performance 3 or 4

排除标准

  • Not provided at time of registration

研究者

发起方
AstraZeneca Clinical Research Group (UK)

相似试验

A Multicentre Randomised and Comparative Trial to... | 临床试验